Abstract
Infliximab is a chimeric monoclonal antibody. Published studies indicate that its use in patients with rheumatoid arthritis can be efficient in providing long-term benefits. The aim of this study is to evaluate the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. A systematic review was performed to search for randomized clinical trials that compared intravenous administration of 3 mg/kg body weight infliximab or placebo in patients concomitantly using methotrexate. Only studies of moderate or high quality were included. A meta-analysis was conducted to assess the efficacy (based on changes of American College of Rheumatology (ACR) criteria) and the safety (based on serious adverse events, serious infections, malignancy, and deaths) of infliximab use. Withdrawals due to adverse events or lack of efficacy were also evaluated in both infliximab-treated and control groups. Seven trials met the inclusion criteria, comprising 2,129 patients. In the efficacy meta-analysis, a greater number of infliximab-treated patients relative to those in the placebo group achieved ACR20, ACR50, and ACR70 values from 14 weeks to 2 years of treatment. For safety analysis, there were no statistically significant differences between the groups. Withdrawals due to adverse events were higher in the infliximab group relative to the placebo group, and withdrawals due to lack of efficacy were higher in the placebo group relative to the infliximab-treated group. This meta-analysis shows a higher efficacy of infliximab relative to placebo without significant safety differences between the infliximab-treated and control groups.
Similar content being viewed by others
References
Tugwell P (2000) Pharmacoeconomics of drug therapy for rheumatoid arthritis. Rheumatology (Oxford) 39(Suppl 1):43–47
Moss ML, Sklair-Tavron L, Nudelman R (2008) Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol 4(6):300–309
Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M et al (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410):675–681
Bértolo M, Brenol C, Schainberg C, Neubarth F (2007) Atualização do consenso brasileiro no diagnóstico e tratamento da artrite reumatóide. Rev Bras Reumatol 47(3):151–159
Fernandez-Nebro A, Irigoyen MV, Urena I, Belmonte-Lopez MA, Coret V, Jimenez-Nunez FG et al (2007) Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. J Rheumatol 34(12):2334–2342
Kanbe K, Inoue K, Inoue Y, Suzuki Y (2008) Histological changes in bone marrow after treatment of infliximab for rheumatoid arthritis. Clin Rheumatol 27(4):497–501
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194):1932–1939
Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D et al (2005) Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52(4):1020–1030
Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR et al (2004) Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 63:149–155
Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358(9285):903–911
Silva RG, Vannucci AB, Latorre LC, Zerbini CAF (2003) Artrite reumatóide. Rev Bras Med 60(8):554–577
Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM (2008) Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Ther 30(11):1939–1955
St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11):3432–3443
Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y et al (2006) A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. J Rheumatol 33(1):37–44
Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343(22):1594–1602
Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S et al (2008) Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 67(8):1096–1103
Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P et al (2006) The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 54(4):1075–1086
Zhang F-C, Hou Y, Huang F, Wu D-H, Bao C-D, Ni L-Q et al (2006) Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China. APLAR J Rheumatol 9(2):127–130
Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJ, Marsters PA et al (2004) Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum 50(4):1107–1116
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12
Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727–735
Hakkinen A, Kautiainen H, Hannonen P, Ylinen J, Makinen H, Sokka T (2006) Muscle strength, pain, and disease activity explain individual subdimensions of the Health Assessment Questionnaire disability index, especially in women with rheumatoid arthritis. Ann Rheum Dis 65(1):30–34
Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J (2006) Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 11(2):193–206
Quinn MA, Conaghan PG, O'connor PJ, Karim Z, Greenstein A, Brown A et al (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52(1):27–35
Smolen JS, van der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E et al (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54(3):702–710
Food and Drug Administration (2006) Arthritis Drugs Advisory Committee: Safety update on TNF antagonists: infliximab and etanercept. http://wwwfdagov/medwatch/SAFETY/2006/May_PIs/Remicade_PIpdfhttp://wwwfdagov/medwatch/SAFETY/2006/May_PIs/Remicade_PIpdf
Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54(8):2368–2376
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098–1104
van der Cruyssen B, Van Looy S, Wyns B, Westhovens R, Durez P, Van den Bosch F et al (2006) Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther 8(4):R112
Pavelka K, Jarosova K, Suchy D, Senolt L, Chroust K, Dusek L et al (2009) Increasing the infliximab dose in rheumatoid arthritis patients: a randomized, double blind study failed to confirm its efficacy. Ann Rheum Dis 68:1285–1289
Disclosures
Astrid Wiens, none; Cassyano Januario Correr, none; Rafael Venson, none; Mônica Cavichiolo Grochocki, none; Michel Fleith Otuki, none; Roberto Pontarolo, none.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wiens, A., Correr, C.J., Venson, R. et al. A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis. Clin Rheumatol 28, 1365–1373 (2009). https://doi.org/10.1007/s10067-009-1233-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-009-1233-9